Efficacy of a blood substitute (Fluosol-DA, 20%) on cerebral ischemia.
Fluosol-DA, 20%, was intravenously infused in 28 patients suffering from cerebrovascular disease, and was found to be effective in 60% of the cases with vasospasm and in 80% of the cases with stenosis and/or occlusion of the artery. Administration of the solution increases r-CBF by 10.1 to 37.9% when measured by either intra-arterial injection or inhalation of 133Xe. However, an increase of arterial oxygen tension appears to have little effect on r-CBF after administration of the solution. The increase of r-CBF caused by Fluosol-DA, 20%, may be due not only to the lowering viscosity of the mixed blood but also to its direct effect on dilating cerebral vessels.
D000328:Adult; D000368:Aged; D001802:Blood Substitutes / Q000008:administration & dosage*; D002545:Brain Ischemia / Q000188:drug therapy*; D002544:Cerebral Infarction / Q000188:drug therapy; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004338:Drug Combinations / Q000008:administration & dosage; D004569:Electroencephalography; D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D007263:Infusions, Parenteral; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood
D001802:Blood Substitutes; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D010100:Oxygen